Erythromycin Lactobionate

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Jun 25, 1964	ErythrocinNDA 50182	Hospira	118	Discontinued
Mar 28, 1985	ErythromycinANDA 62563	Elkins Sinn	10	Discontinued
Sep 24, 1986	ErythrocinNDA 50609 · New dosage form	Hospira	22	Marketed
Oct 31, 1986	ErythrocinANDA 62638	Hospira	21	Marketed
Jan 4, 1988	ErythrocinANDA 62586	Abbott	0	Discontinued
May 9, 1989	Erythromycin LactobionateANDA 62993	Baxter Hlthcare	3	Discontinued
Jul 30, 1993	Erythromycin LactobionateANDA 63253	Teva Parenteral	1	Discontinued
Sep 17, 2020	Erythromycin LactobionateANDA 211086	Exela Pharma	0	Discontinued
Feb 14, 2022	Erythromycin LactobionateANDA 215290	Nexus	0	Marketed
Nov 19, 2024	Erythromycin LactobionateANDA 216761	Gland	0	Marketed
—	Erythromycin LactobionateANDA 62604	Abraxis Pharm	0	Discontinued
—	Erythromycin LactobionateANDA 62660	Quad Pharms	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA